DSY Dassault Systemes SA

Update: Dassault Systèmes: Medidata Extends Collaboration with Sanofi for the Development of New Therapies with an Improved Patient Journey

Update: Dassault Systèmes: Medidata Extends Collaboration with Sanofi for the Development of New Therapies with an Improved Patient Journey

Medidata Extends Collaboration with Sanofi for the Development of New Therapies with an Improved Patient Journey 

Expanded 10-plus-year collaboration will leverage Medidata Experiences with the goal of streamlining clinical processes and data, enhancing patient care

New York – Oct. 23, 2025 –, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced an extension of their collaboration with Sanofi in clinical research. As part of this extension Sanofi will use the , building on the organizations’ vision to boost innovation in studies, speed new therapies to market, and promote health outcomes for people globally.

The Medidata Experiences address the fragmented, standalone tools of the life sciences industry by offering AI-embedded, platform-based solutions across clinical workflows, unifying trial processes, diminishing silos, and reducing costs and delays. Combining these Experiences with Sanofi’s pharmaceutical knowledge can help advance studies, amplifying the development of therapies with greater precision and impact.

Sanofi will employ Medidata’s expertise and capabilities in as part of the extension of this agreement. Medidata will provide consulting and end-to-end operational support.

“Clinical development is complex, and biopharma companies demand a strategic partner who can help them enhance data quality, improve study design, and elevate patient care," said Lisa Moneymaker, chief strategy officer, Medidata. "Through this agreement, Sanofi can leverage our unified solutions, specifically mapped out to meet their core needs, to simplify execution and accelerate the clinical development process.”

To learn more about the Medidata Experiences, please visit .

About Medidata

Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. Celebrating 25 years of ground-breaking technological innovation across more than 36,000 trials and 11 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and one of the largest clinical trial data sets in the industry. More than 1 million registered users across approximately 2,300 customers trust Medidata’s seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. A Dassault Systèmes brand (Euronext Paris: FR0014003TT8, DSY.PA), Medidata is headquartered in New York City and has been recognized as a Leader by Everest Group and IDC. Discover more at . Listen to our latest podcast, , and follow us at @Medidata.

About Dassault Systèmes

Dassault Systèmes is a catalyst for human progress. Since 1981, the company has pioneered virtual worlds to improve real life for consumers, patients and citizens. With Dassault Systèmes’ 3DEXPERIENCE platform, 370,000 customers of all sizes, in all industries, can collaborate, imagine and create sustainable innovations that drive meaningful impact. For more information, visit: .

Contact:

Medidata PR

Analyst Relations

Attachment



EN
28/10/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Dassault Systemes SA

 PRESS RELEASE

Dassault Systèmes: Q4 revenue growth of 1% with solid operating margin...

Dassault Systèmes: Q4 revenue growth of 1% with solid operating margin and EPS expansion Initiating 2026 revenue guidance of 3-5% growth Press Release VELIZY-VILLACOUBLAY, France — February 11, 2026 Dassault Systèmes: Q4 revenue growth of 1% with solid operating margin and EPS expansion Initiating 2026 revenue guidance of 3-5% growth            (Euronext Paris: FR0014003TT8, DSY.PA) today reports its IFRS unaudited estimated financial results for the fourth quarter 2025 and full-year ended December 31, 2025. The Group’s Board of Directors approved these estimated results on February...

 PRESS RELEASE

Dassault Systèmes : Chiffre d’affaires T4 en hausse de 1%, marge opéra...

Dassault Systèmes : Chiffre d’affaires T4 en hausse de 1%, marge opérationnelle solide et progression du BNPA ; Pour 2026, objectif de croissance de 3% à 5% du chiffre d’affaires         Communiqué de Presse VELIZY-VILLACOUBLAY, France — 11 février 2026 Dassault Systèmes : Chiffre d’affaires T4 en hausse de 1%, marge opérationnelle solide et progression du BNPA ; Pour 2026, objectif de croissance de 3% à 5% du chiffre d’affaires    (Euronext Paris : FR0014003TT8, DSY.PA) annonce aujourd’hui ses résultats financiers estimés non-audités en IFRS pour le quatrième trimestre 2025 et l’ex...

 PRESS RELEASE

Dassault Systèmes: declaration of the number of outstanding shares and...

Dassault Systèmes: declaration of the number of outstanding shares and voting rights as of January 31, 2026 Press ReleaseVELIZY-VILLACOUBLAY, France — February 9, 2026                 Declaration of the number of outstanding shares and voting rights as of January 31, 2026 (Euronext Paris: FR0014003TT8, DSY.PA) today announced below the total number of its outstanding shares and voting rights as of January 31, 2026, according to articles 223-16 and 221-3 of the General Regulation of the Autorité des marchés financiers. Number of outstanding shares: 1,341,809,943 Number of voting rights*...

 PRESS RELEASE

Dassault Systèmes : déclaration du nombre d'actions et de droits de vo...

Dassault Systèmes : déclaration du nombre d'actions et de droits de vote au 31 janvier 2026 Communiqué de PresseVELIZY-VILLACOUBLAY, France — le 9 février 2026 Déclaration du nombre d’actions et de droits de voteau 31 janvier 2026         (Euronext Paris : FR0014003TT8, DSY.PA) annonce ci-après le nombre total d’actions composant son capital et le nombre total de ses droits de vote au 31 janvier 2026, conformément aux articles 223-16 et 221-3 du Règlement Général de l’Autorité des marchés financiers. Nombre d'actions en circulation : 1 341 809 943 Nombre de droits de vote* : 2 013 517 ...

 PRESS RELEASE

Dassault Systèmes: Half-year statement of the Liquidity contract enter...

Dassault Systèmes: Half-year statement of the Liquidity contract entered into with Oddo BHF SCA Press ReleaseVELIZY-VILLACOUBLAY, France — January 12, 2026 Half-year statement of the Liquidity contract entered into with Oddo BHF SCA (Euronext Paris: FR0014003TT8, DSY.PA) announces that the following resources appeared on December 31, 2025 on the liquidity contract entered into with Oddo BHF SCA implemented on January 7, 2015 and updated on June 18, 2019:      925,197 Dassault Systèmes shares, and€ 5,384,754.01 in cash. It is reminded that: at the time of the implementation of the liqu...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch